Based on the profound inhibitory effects of the PEGylated FA-MTX-MNPs in the FR-positive cancer cells through PI3K/AKT pathway, we propose this FR-targeting NS as a robust site-specific targeted delivery nanomedicine and theranostic that can be used against various FR-positive malignancies. The gene discussed is AKT1; the disease is cancer.